Status:
UNKNOWN
Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis
Lead Sponsor:
Nanjing Medical University
Conditions:
Renal Cirrhosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. The potential for stem cells to treat kidney failure was recently confirmed. Particularly, mesenchym...
Detailed Description
Kidney fibrosis represents the common pathway to end-stage kidney failure.The potential for stem cells to treat kidney failure was recently confirmed. In particular, mesenchymal stem cell (MSC) transp...
Eligibility Criteria
Inclusion
- Written informed consent.
- Glomerular sclerosis ratio ≤ 50%.
- Renal tubulointerstitial fibrosis ratio ≤ 50%.
- Negative pregnancy test.
- Moderately active disease under standard treatment.
Exclusion
- 1\. Severe infection and cardiovascular disease, shock, secondary liver disease and malignant tumor.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03460223
Start Date
April 1 2018
End Date
September 1 2020
Last Update
March 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.